Allianz agreed on July 24, 2026, to acquire HSBC Holdings plc’s Singapore life and health insurance unit for about S$2.7 billion (around US$2.1 billion) [1, 2, 3, 4, 5]. The transaction includes a 15-year exclusive bancassurance distribution partnership, enabling Allianz to offer insurance products through HSBC Singapore’s network [1, 2, 3, 4, 5].
The deal is expected to complete in the first half of 2027, pending regulatory approvals across relevant jurisdictions [1, 2, 3, 4, 5]. HSBC Life Singapore employees will be retained by Allianz after completion, helping ensure operational continuity [2].
HSBC expects to book a pre-tax gain of roughly US$1.8 billion from the disposal [1, 2, 3, 4]. HSBC Life Singapore posted a pre-tax profit of S$118 million in 2025 and an operating profit of €80 million (about US$91 million) according to HSBC’s most recent figures [3, 4, 5]. Despite the sale, HSBC affirmed its strong commitment to Singapore as a wealth and wholesale banking hub [1, 3, 4].
The deal will boost HSBC’s common equity tier 1 ratio by up to 15 basis points once completed [2, 3, 4]. An initial S$200 million cash payment is part of the bancassurance distribution agreement component [2, 3, 4]. Allianz noted the acquisition expands its footprint in Singapore, a leading financial center in Asia. The insurer said the expanded presence strengthens its position in one of Asia’s most attractive insurance markets and financial hubs [1, 3, 4, 5]. Renate Wagner, Allianz board member, said the acquisition will allow the group "to support more individuals and communities even more comprehensively, with a broader product portfolio that helps protect and plan for what matters most to them" [5].
This marks Allianz’s renewed push into the Singapore insurance market after withdrawing a 2024 bid to buy a majority stake in Income Insurance Ltd for about S$2.2 billion [1, 3, 4].
HSBC and Allianz officially announced their agreement on July 24, 2026 [1, 2, 3, 4, 5]. The deal completion is targeted for the first half of 2027, pending regulatory approval [1, 2, 3, 4, 5].
